Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 120

1.

A multicolor fluorescence in situ hybridization assay: A monitoring tool in the surveillance of patients with a history of non-muscle-invasive urothelial cell carcinoma: A prospective study.

Galván AB, Salido M, Espinet B, Placer J, Pijuan L, Juanpere N, Lloreta J, Solé F, Gelabert-Mas A.

Cancer Cytopathol. 2011 Dec 25;119(6):395-403. doi: 10.1002/cncy.20168. Epub 2011 Jun 29.

2.
3.

[Independent multiple primary tumors and second primary neoplasms. Relationship between smoking].

las Heras Alonso MM, Gelabert Mas A.

Actas Urol Esp. 2010 Jun;34(6):516-21. Review. Spanish.

PMID:
20510114
4.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

5.

[Changing paradigms in the diagnosis (primary and of recurrences) and the treatment of urothelial cancer: preparing the future].

Gelabert Mas A.

Actas Urol Esp. 2009 Jul-Aug;33(7):725-7. Spanish. No abstract available.

PMID:
19757654
6.

[New cell target treatments: indications, results and tolerance].

Bellmunt J, Gelabert-Mas A.

Actas Urol Esp. 2009 May;33(5):609-14. Spanish. No abstract available.

PMID:
19658316
7.

Phase II study of vinorelbine and estramustine in combination with conformational radiotherapy for patients with high-risk prostate cancer.

Carles J, Nogue M, Sole JM, Foro P, Domenech M, Suarez M, Gallardo E, García D, Ferrer F, Gelabert-Mas A, Gayo J, Fabregat X.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1085-91. doi: 10.1016/j.ijrobp.2009.03.024. Epub 2009 Jul 4.

PMID:
19577864
8.

Holmium laser enucleation of prostate: outcome and complications of self-taught learning curve.

Placer J, Gelabert-Mas A, Vallmanya F, Manresa JM, Menéndez V, Cortadellas R, Arango O.

Urology. 2009 May;73(5):1042-8. doi: 10.1016/j.urology.2008.12.052.

PMID:
19394500
9.

[Combined modality treatment: a new horizon in oncological urology. Praxis and monotherapy concept decline].

Gelabert Mas A.

Actas Urol Esp. 2008 Sep;32(8):771-2. Spanish. No abstract available.

PMID:
19013973
10.

[Oncologically safe simplified nephroureterectomy: combination with percutaneous ureteral the ligation-section].

Gelabert Mas A, Hernández del Pozo H, Placer Santos J.

Arch Esp Urol. 2008 May;61(4):521-3. Spanish.

PMID:
18592771
11.

[Urethral leiomyoma].

Vallmanya Llena FR, Rijo Mora E, Hernández Pozo H, Del Canto Aguirre M, Lorente Garin JA, Gelabert Mas A.

Actas Urol Esp. 2007 Nov-Dec;31(10):1196. Spanish. No abstract available.

PMID:
18314663
12.

[Localization of sentinel node in squamous cell carcinoma of the penis. Initial experience].

Rubí S, Vidal-Sicar S, Ortega M, Doménech B, Lafuente S, Corral JM, Gelabert-Mas A.

Rev Esp Med Nucl. 2008 Jan-Feb;27(1):3-7. Spanish.

13.

[Field notebooks and histologic drawings in the work of Salvador Gil Vernet].

Gelabert Mas A.

Arch Esp Urol. 2007 Oct;60(8):979-83. Spanish.

PMID:
18050763
14.

[Vesical hernia].

Rijo Mora EA, Vallmanya Llena FR, Hernández Pozo H, Del Canto Aguirre M, Lorente Garín JA, Gelabert Mas A.

Actas Urol Esp. 2007 Sep;31(8):938. Spanish. No abstract available.

PMID:
18020223
15.

[Treatment of renal cell carcinoma: new opportunity for coordination between uro-oncology and oncology].

Gelabert Mas A.

Actas Urol Esp. 2007 Sep;31(8):805-6. Spanish. No abstract available.

PMID:
18020202
16.

[The therapeutic indication: is it an immutable category?].

Gelabert Mas A.

Arch Esp Urol. 2006 Oct;59(8):763-5. Spanish. No abstract available.

PMID:
17153493
17.

Detrusor quantitative morphometry in obstructed males and controls.

Collado A, Batista E, Gelabert-Más A, Corominas JM, Arañó P, Villavicencio H.

J Urol. 2006 Dec;176(6 Pt 1):2722-8.

PMID:
17085203
18.

[Development of tissue microarray technology (TMA) for immunohistochemical study of molecular expression profiling in prostate cancer (part 1)].

Lorente Garín JA, Lloreta Trull J, Allepuz Losa C, Plaza Mas L, Rioja Sanz LA, Gelabert Mas A.

Actas Urol Esp. 2006 Jan;30(1):25-32. Spanish.

PMID:
16703726
19.

Tuberous sclerosis complex. Forty-years of follow-up of a patient affected.

Vallmanya F, Placer J, Pou Serradell A, Cortadellas R, Gelabert-Mas A.

Arch Esp Urol. 2006 Jan-Feb;59(1):105-7.

PMID:
16568704
20.

Insertion (8;11) in a renal oncocytoma with multifocal transformation to chromophobe renal cell carcinoma.

Salido M, Lloreta J, Melero C, García M, Placer J, Espinet B, Villa O, Bielsa O, Gelabert-Mas A, Serrano S, Solé F.

Cancer Genet Cytogenet. 2005 Dec;163(2):160-3.

PMID:
16337860

Supplemental Content

Loading ...
Support Center